The development, past achievements, and future directions of brain PET

Journal of Cerebral Blood Flow and Metabolism

Volumn 32, Issue 7, 2012, Pages 1426-1454

  Jones, Terry ^a,b   Rabiner, Eugenii A ^c,d  

^a PET Research Advisory Company   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Imanova Ltd   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Advances; brain; disorders; drug development; PET; physiology

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 3 METHYLSPIPERONE C 11; 3' FLUOROTHYMIDINE F 18; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; 6 FLUORODOPA F 18; 8 AZIDO 5,6 DIHYDRO 5 METHYL 6 OXO 4H IMIDAZO[1,5 A][1,4]BENZODIAZEPINE 3 CARBOXYLIC ACID ETHYL ESTER; ABP 688; AZ 10419369; CARFENTANIL; CARMUSTINE; DIPRENORPHINE; FBL 457; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; GSK 215083; GSK 931145; HARMINE; MCNEIL 5652; METHIONINE C 11; MK 9470; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N METHYLTRYPTOPHAN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NOMIFENSINE; P 943; PSYCHOTROPIC AGENT; RACLOPRIDE C 11; SB 207145; SCHERING 23390; SELEGILINE; SP 203; TEMOZOLOMIDE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VOLINANSERIN;

ADDICTION; ANXIETY DISORDER; BRAIN FUNCTION; BRAIN TUMOR; CEREBROVASCULAR DISEASE; CYCLOTRON; DEMENTIA; DEPRESSION; EPILEPSY; HUMAN; MEDICAL RESEARCH; MOTOR DYSFUNCTION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN; BRAIN DISEASES; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84863454741     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.20     Document Type: Review

References (277)

1. Abanades S, Van Der Aart J, Barletta JAR, Marzano C, Searle GE, Salinas CA, Ahmad JJ, Reiley RR, Pampols-Maso S, Zamuner S, Cunningham VJ, Rabiner EA, Laruelle MA, Gunn RN (2011) Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 31:944-52
2. Ackerman RH, Correia JA, Alpert NM, Baron JC, Gouliamos A, Grotta JC, Brownell GL, Taveras JM (1981) Positron imaging in ischemic stroke disease using compounds labeled with oxygen 15. Initial results of clinicophysiologic correlations. Arch Neurol 38:537-43 (Pubitemid 11061653)
3. Alavi A, Reivich M (2002) Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med 32:2-5 (Pubitemid 34112938)
4. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AA (1996) Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47:462-6 (Pubitemid 26324044)
5. Andersson JD, Pierson ME, Finnema SJ, Gulyas B, Heys R, Elmore CS, Farde L, Halldin C (2011) Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nucl Med Biol 38:261-72
6. Ashburner J, Haslam J, Taylor C, Cunningham VJ, Jones T (1996) A cluster analysis approach for the characterization of dynamic PET data. In: Quantification of brain function using PET (Myers R, Cunningham VJ, Bailey D, Jones T, eds), San Diego: Academic Press, 301-6
7. Ashworth S, Rabiner EA, Gunn RN, Plisson C, Wilson AA, Comley RA, Lai RYK, Gee AD, Laruelle M, Cunningham VJ (2010) Evaluation of 11C-GSK189254 as a novel radioligand for the H 3 receptor in humans using PET. J Nucl Med 51:1021-9
8. Bacher I, Houle S, Xu X, Zawertailo L, Soliman A, Wilson AA, Selby P, George TP, Sacher J, Miler L, Kish SJ, Rusjan P, Meyer JH (2011) Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry 68:817-26
9. Baciu M, Sebai SC, Ces O, Mulet X, Clarke JA, Shearman GC, Law RV, Templer RH, Plisson C, Parker CA, Gee A (2006) Degradative transport of cationic amphiphilic drugs across phospholipid bilayers. Philos Transact A Math Phys Eng Sci 364:2597-614 (Pubitemid 44661775)
10. Badgaiyan RD, Fischman AJ, Alpert NM (2007) Striatal dopamine release in sequential learning. Neuroimage 38:549-56 (Pubitemid 47539910)
11. Baron JC, Bousser MG, Comar D, Castaigne P (1980) Crossed cerebellar diaschisis" in human supratentorial brain infarction. Trans Am Neurol Assoc 105: 459-461
12. Baron JC, Bousser MG, Comar D, Soussaline F, Castaigne P (1981a) Noninvasive tomographic study of cerebral blood flow and oxygen metabolism in vivo. Potentials, limitations, and clinical applications in cerebral ischemic disorders. Eur Neurol 20:273-84 (Pubitemid 11087763)
13. Baron JC, Bousser MG, Rey A, Guillard A, Comar D, Castaigne P (1981b) Reversal of focal 'misery-perfusion syndrome' by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 15O positron emission tomography. Stroke 12:454-9 (Pubitemid 11046690)
14. Baron JC, Comar D, Soussaline F, Todd-Pokropek AE, Bousser MG, Castaigne P, Kellersholhn C (1979) Continuous 15O inhalation technique: an attempt to quantify CBF, EO2 and CMRO2. Acta Neurol Scand 60:194-5
15. Baron JC, Jones T (2011) Oxygen metabolism, oxygen extraction and positron emission tomography: historical perspective and impact on basic and clinical neuroscience. Neuroimage (e-pub ahead of print)
16. Baron JC, Rougemont D, Soussaline F, Bustany P, Crouzel C, Bousser MG, Comar D (1984) Local interrelationships of cerebral oxygen consumption and glucose utilization in normal subjects and in ischemic stroke patients: a positron tomography study. J Cereb Blood Flow Metab 4:140-9 (Pubitemid 14080142)
17. Barrio JR, Keen RE, Ropchan JR, MacDonald NS, Baumgartner FJ, Padgett HC, Phelps ME (1983) L-[1-11C]leucine: routine synthesis by enzymatic resolution. J Nucl Med 24:515-21 (Pubitemid 13034538)
18. Bartenstein PA, Duncan JS, Prevett MC, Cunningham VJ, Fish DR, Jones AK, Luthra SK, Sawle GV, Brooks DJ (1993) Investigation of the opioid system in absence seizures with positron emission tomography. J Neurol Neurosurg Psychiatry 56:1295-302 (Pubitemid 24008465)
19. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-73 (Pubitemid 41032989)
20. Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, Cuddigan M, Turton DJ, Osman S, Frackowiak RSJ (1993) Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology 112:308-14 (Pubitemid 23278294)
21. Benson DF, Kuhl DE, Hawkins RA, Phelps ME, Cummings JL, Tsai SY (1983) The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neurol 40:711-4 (Pubitemid 14230505)
22. Bergstrom M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T, Halldin C, von Holst H, Langstrom B, Lilja A, Lundqvist H, Nagren K (1983) Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 7:1062-6 (Pubitemid 14246648)
23. Bergstrom M, Grahnen A, Langstrom B (2003) Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59:357-66 (Pubitemid 37214939)
24. Bergström M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ögren M, Antoni G, La°ngström B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55:1007-12 (Pubitemid 38581916)
25. Bergstrom M, Yates R, Wall A, Kagedal M, Syvanen S, Langstrom B (2006) Blood-brain barrier penetration of zolmitriptan-Modelling of positron emission tomography data. J Pharmacokinet Pharmacodyn 33:75-91
26. Bernow N, Yakushev I, Landvogt C, Buchholz HG, Smolka MN, Bartenstein P, Lieb K, Grunder G, Vernaleken I, Schreckenberger M, Fehr C (2011) Dopamine D2/D3 receptor availability and venturesomeness. Psychiatry Res 193:80-4
27. Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P (2006) Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am J Psychiatry 163:1580-7 (Pubitemid 44465759)
28. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ (2004) Persistent reductions in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 9:386-92 (Pubitemid 38534699)
29. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745-8 (Pubitemid 37521630)
30. Bouvard S, Costes N, Bonnefoi F, Lavenne F, Mauguiere F, Delforge J, Ryvlin P (2005) Seizure-related shortterm plasticity of benzodiazepine receptors in partial epilepsy: a [11C]flumazenil-PET study. Brain 128: 1330-43 (Pubitemid 40826187)
31. Breier A, Kestler L, Adler C, Elman I, Wiesenfeld N, Malhotra A, Pickar D (1998) Dopamine D2 receptor density and personal detachment in healthy subjects. Am J Psychiatry 155:1440-2 (Pubitemid 28471204)
32. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-74 (Pubitemid 27136916)
33. Brownell GL, Sweet WH (1953) Localization of brain tumours with positron emitters. Nucleonics 11:40-5
34. Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA (2011) Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 134:1647-57
35. Burnham CA, Brownell GL (1972) A multi-crystal positron camera. IEEE Trans Nucl Sci 19:201-5
36. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet 358:461-7 (Pubitemid 32769854)
37. Calautti C, Leroy F, Guincestre JY, Baron JC (2001) Dynamics of motor network overactivation after striatocapsular stroke: a longitudinal PET study using a fixedperformance paradigm. Stroke 32:2534-42 (Pubitemid 33055302)
38. Carson RE (2003) Tracer kinetic modeling in PET. In: Positron emission tomography: basic science and clinical practice (Valk PE, Bailey D, Townsend DW, Maisey MN, eds). London: Springer-Verlag
39. Casey ME, Nutt R (1986) A multicrystal two dimensional BGO detector system for positron emission tomography. IEEE Trans Nucl Sci 33:460-3
40. Cervenka S, Backman L, Cselenyi Z, Halldin C, Farde L (2008) Associations between dopamine D2-receptor binding and cognitive performance indicate functional compartmentalization of the human striatum. Neuroimage 40:1287-95
41. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH (2005) Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46:945-52 (Pubitemid 43733508)
42. Cherry SR, Shao Y, Siegel S, Silverman RW, Meadors K, Young J, JonesWF, Newport D,Mooyers C, Mumcuoglu EU, Chatziioannou A, Farquhar T, Andreaco M, Paulus M, Binkley D, Nutt R, Phelps ME (1996) MicroPET: a high resolution PET scanner for imaging small animals. IEEE Nuclear Science Symposium (Conference Record) 2:1120-4
43. Chesler DA (1973) Positron tomography and three-dimensional reconstruction. In: Tomographic imaging in nuclear medicine (Freedman GS, ed). New York: Society of Nuclear Medicine
44. Chollet F, DiPiero V, Wise RJ, Brooks DJ, Dolan RJ, Frackowiak RS (1991) The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. Ann Neurol 29:63-71
45. Christian BT, Vandehey NT, Floberg JM, Mistretta CA (2010) Dynamic PET denoising with HYPR processing. J Nucl Med 51:1147-54
46. Chugani HT, Kumar A, Kupsky W, Asano E, Sood S, Juhasz C (2011) Clinical and histopathologic correlates of 11Calpha-methyl-L-tryptophan (AMT) PET abnormalities in children with intractable epilepsy. Epilepsia 52:1692-8
47. Chugani HT, Phelps ME (1986) Maturational changes in cerebral function in infants determined by 18FDG positron emission tomography. Science 231:840-3 (Pubitemid 16213042)
48. Coope DJ, Cizek J, Eggers C, Vollmar S, Heiss WD, Herholz K (2007) Evaluation of primary brain tumors using 11Cmethionine PET with reference to a normal methionine uptake map. J Nucl Med 48:1971-80 (Pubitemid 350232305)
49. Cunningham VJ, Jones T (1993) Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 13:15-23 (Pubitemid 23016599)
50. Cunningham VJ, Parker CA, Rabiner EA, Gee AD, Gunn RN (2005) PET studies in drug development: methodological considerations. Drug Discov Today Technol 2:311-5 (Pubitemid 43115466)
51. De la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001) Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293:1164-6 (Pubitemid 32758101)
52. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV (1988) Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 150:189-97 (Pubitemid 18027033)
53. Diksic M, Sako K, Feindel W, Kato A, Yamamoto YL, Farrokhzad S, Thompson C (1984) Pharmacokinetics of positron-labeled 1,3-bis(2-chloroethyl)nitrosourea in human brain tumors using positron emission tomography. Cancer Res 44:3120-4 (Pubitemid 14081452)
54. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2003) Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60:601-5 (Pubitemid 36246076)
55. Dolan RJ, Fink GR, Rolls E, Booth M, Holmes A, Frackowiak RS, Friston KJ (1997) How the brain learns to see objects and faces in an impoverished context. Nature 389:596-9 (Pubitemid 27446175)
56. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, Huang Y, Gautier C, Mathis C (1999) PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 46:1375-87
57. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S, Fahn S (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14: 783-801 (Pubitemid 24266530)
58. Farde L (1996) The advantage of using positron emission tomography in drug research. Trends Neurosci 19:211-4 (Pubitemid 26167811)
59. Farde L, Gustavsson JP, Jonsson E (1997) D2 dopamine receptors and personality traits. Nature 385:590 (Pubitemid 27087565)
60. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-44
61. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-6 (Pubitemid 18018572)
62. Feigin A, Leenders KL, Moeller JR, Missimer J, Kuenig G, Spetsieris P, Antonini A, Eidelberg D (2001) Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 42:1591-5 (Pubitemid 33131316)
63. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D (2007) Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130:2858-67 (Pubitemid 350033965)
64. Feldmann M (2011) Personal communication
65. Fox PT, Burton H, Raichle ME (1987a) Mapping human somatosensory cortex with positron emission tomography. J Neurosurg 67:34-43 (Pubitemid 17085010)
66. Fox PT, Miezin FM, Allman JM, Van Essen DC, Raichle ME (1987b) Retinotopic organization of human visual cortex mapped with positron-emission tomography. J Neurosci 7:913-22 (Pubitemid 17032609)
67. Fox PT, Raichle ME (1986) Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc Natl Acad Sci USA 83:1140-4 (Pubitemid 16086428)
68. Frackowiak RS, Lenzi GL, Jones T, Heather JD (1980) Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr 4:727-36 (Pubitemid 11247403)
69. Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, Jones T (1981) Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104:753-78 (Pubitemid 12235670)
70. Frankle WG, Cho RY, Narendran R, Mason NS, Vora S, Litschge M, Price JC, Lewis DA, Mathis CA (2009) Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects. Neuropsychopharmacology 34:624-33
71. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-9 (Pubitemid 32204988)
72. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJ, Snow BJ, Calne DB, Gauger LL (1995) Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 38:379-88
73. Freis ED (1954) Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 251:1006-8
74. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE (1983) Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 7:590-8 (Pubitemid 13035941)
75. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ (1994) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210 (Pubitemid 124008664)
76. Frokjaer VG, Mortensen EL, Nielsen FA, Haugbol S, Pinborg LH, Adams KH, Svarer C, Hasselbalch SG, Holm S, Paulson OB, Knudsen GM (2008) Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry 63:569-76 (Pubitemid 351273195)
77. Frokjaer VG, Vinberg M, Erritzoe D, Baare W, Holst KK, Mortensen EL, Arfan H, Madsen J, Jernigan TL, Kessing LV, Knudsen GM (2010) Familial risk for mood disorder and the personality risk factor, neuroticism, interact in their association with frontolimbic serotonin 2A receptor binding. Neuropsychopharmacology 35: 1129-37
78. Frokjaer VG, Vinberg M, Erritzoe D, Svarer C, Baare W, Budtz-Joergensen E, Madsen K, Madsen J, Kessing LV, Knudsen GM (2009) High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage 46:360-6
79. Frost JJ, Mayberg HS, Fisher RS, Douglass KH, Dannals RF, Links JM,Wilson AA, Ravert HT, Rosenbaum AE, Snyder SH, Wagner Jr HN (1988) Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 23:231-7 (Pubitemid 18086150)
80. Gallezot JD, Nabulsi N, Neumeister A, Planeta-Wilson B, Williams WA, Singhal T, Kim S, Maguire RP, McCarthy T, Frost JJ, Huang Y, Ding YS, Carson RE (2010) Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. J Cereb Blood Flow Metab 30:196-210
81. Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia of living man. Nature 305:137-8 (Pubitemid 14235666)
82. Garraux G, Peigneux P, Carson RE, Hallett M (2007) Taskrelated interaction between basal ganglia and cortical dopamine release. J Neurosci 27:14434-41
83. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB (2005) Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage 24:591-5 (Pubitemid 41359057)
84. Gibbs JM, Wise RJ, Leenders KL, Jones T (1984) Evaluation of cerebral perfusion reserve in patients with carotidartery occlusion. Lancet 1:310-4 (Pubitemid 14185337)
85. Ginovart N, Meyer JH, Boovariwala A, Hussey D, Rabiner EA, Houle S, Wilson AA (2006) Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 26:330-44
86. Goerendt IK, Messa C, Lawrence AD, Grasby PM, Piccini P, Brooks DJ (2003) Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain 126:312-25 (Pubitemid 36172738)
87. Goffin K, Van Paesschen W, Van Laere K (2011) In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain 134:1033-40
88. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28:2000-9 (Pubitemid 37412109)
89. Guadagno JV, Jones PS, Aigbirhio FI, Wang D, Fryer TD, Day DJ, Antoun N, Nimmo-Smith I, Warburton EA, Baron JC (2008) Selective neuronal loss in rescued penumbra relates to initial hypoperfusion. Brain 131: 2666-78
90. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279-87 (Pubitemid 28018717)
91. Gunn RN, Salinas CA, Read KR, Searle G, Ruffo AD, Parker CA, Stevens AJ, Bonasera T, Jeffrey PM, Laruelle MA (2007) Combining PET and equilibrium dialysis to assess blood-brain-barrier transport. J Cereb Blood Flow Metab 27:4-14
92. Guo Q, Brady M, Gunn RN (2009) A biomathematical modeling approach to central nervous system radioligand discovery and development. J Nucl Med 50: 1715-1723
93. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen H-C, Stovner LJ, Vallat J-M, den Bergh PV, van Os J, Vos P, Xu W, Wittchen H-U, Jönsson B, Olesen J (2011) Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:718-79
94. Hamill TG, Lin LS, Hagmann W, Liu P, Jewell J, Sanabria S, Eng W, Ryan C, Fong TM, Connolly B, Vanko A, Hargreaves R, Goulet MT, Burns HD (2009) PET imaging studies in rhesus monkey with the cannabinoid-1 (CB1) receptor ligand [11C]CB-119. Mol Imaging Biol 11:246-52
95. Hammers A, Asselin MC, Hinz R, Kitchen I, Brooks DJ, Duncan JS, Koepp MJ (2007) Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 130:1009-16 (Pubitemid 47355596)
96. Hammers A, Koepp MJ, Richardson MP, Labbe C, Brooks DJ, Cunningham VJ, Duncan JS (2001) Central benzo-diazepine receptors in malformations of cortical development: a quantitative study. Brain 124:1555-65 (Pubitemid 32726769)
97. Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, Dohmen BM, Braus DF, Schumann G, Machulla HJ, Bares R, Mann K (2005a) Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62:57-64 (Pubitemid 40096071)
98. Heinz A, Siessmeier T, Wrase J, Buchholz HG, Grunder G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rosch F, Mann K, Bartenstein P (2005b) Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 162:1515-20 (Pubitemid 41105567)
99. Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G (2001) Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 124:20-9 (Pubitemid 32055986)
100. Herholz K (2010) Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert Rev Neurother 10:1667-73
101. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U, Vuorio K, Rakkolainen V, Bergman J, Solin O, Kirvela O, Salokangas RKR (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130-1
102. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD (2005) Dementia in Parkinson disease. Neurology 65:1716-22
103. Hoffman EJ, Huang SC, Phelps ME (1979) Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3:299-308 (Pubitemid 9176236)
104. Hostetler ED, Eng W, Joshi AD, Sanabria-Bohorquez S, Kawamoto H, Ito S, O'Malley S, Krause S, Ryan C, Patel S, Williams M, Riffel K, Suzuki G, Ozaki S, Ohta H, Cook J, Burns HD, Hargreaves R (2011a) Synthesis, characterization, and monkey PET studies of [(1)F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse 65:125-35
105. Hostetler ED, Sanabria-Bohorquez S, Fan H, Zeng Z, Gantert L, Williams M, Miller P, O'Malley S, Kameda M, Ando M, Sato N, Ozaki S, Tokita S, Ohta H, Williams D, Sur C, Cook JJ, Burns HD, Hargreaves R (2011b) Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor. Neuroimage 54:2635-42
106. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66:13-20
107. Hubner KF, Krauss S, Washburn LC, Gibbs WD, Holloway EC (1981) Tumor detection with 1-aminocyclopentane and 1-aminocyclobutane C-11-carboxylic acid using positron emission computerized tomography. Clin Nucl Med 6:249-52 (Pubitemid 11125759)
108. Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, Kuhl DE (1978) Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J Labelled Comp Radiopharm 14:175-83 (Pubitemid 8294308)
109. Ishii K, Sakamoto S, Sasaki M, Kitagaki H, Yamaji S, Hashimoto M, Imamura T, Shimomura T, Hirono N, Mori E (1998) Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 39: 1875-8 (Pubitemid 28518885)
110. Jack Jr CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133:3336-48
111. Jiang Z, Reilly J, Everatt B, Briard E (2011) A rapid vesicle electrokinetic chromatography method for the in vitro prediction of non-specific binding for potential PET ligands. J Pharm Biomed Anal 54:722-9
112. Johnson S, Stockmeier CA, Meyer JH, Austin MC, Albert PR,Wang J, May WL, Rajkowska G, Overholser JC, Jurjus G, Dieter L, Johnson C, Sittman DB, Ou XM (2011) The reduction of R1, a novel repressor protein for monoamine oxidase a, in major depressive disorder. Neuropsychopharmacology 36:2139-48
113. Jones T, Chesler DA, Ter-Pogossian MM (1976) The continuous inhalation of oxygen-15 for assessing regional oxygen extraction in the brain of man. Br J Radiol 49:339-43
114. Kadrmas DJ, Casey ME, Conti M, Jakoby BW, Lois C, Townsend DW (2009) Impact of time-of-flight on PET tumor detection. J Nucl Med 50:1315-23
115. Kalbitzer J, Erritzoe D, Holst KK, Nielsen FA, Marner L, Lehel S, Arentzen T, Jernigan TL, Knudsen GM (2010) Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry 67:1033-9
116. Kalbitzer J, Frokjaer VG, Erritzoe D, Svarer C, Cumming P, Nielsen FA, Hashemi SH, Baare WF, Madsen J, Hasselbalch SG, Kringelbach ML, Mortensen EL, Knudsen GM (2009) The personality trait openness is related to cerebral 5-HTT levels. Neuroimage 45:280-5
117. Kapoor RR, Gilbert C, Mohnike K, Blankenstein O, Fuechtner F, Hussain K (2009) Congenital hyperinsulinism: [F]DOPA PET/CT scan of a focal lesion in the head of the pancreas. BMJ Case Rep 2009:bcr2007121178
118. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R (1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 153:948-50 (Pubitemid 26225470)
119. Karabanov A, Cervenka S, de Manzano O, Forssberg H, Farde L, Ullen F (2010) Dopamine D2 receptor density in the limbic striatum is related to implicit but not explicit movement sequence learning. Proc Natl Acad Sci USA 107:7574-9
120. Karlsson H, Hirvonen J, Kajander J, Markkula J, Rasi-Hakala H, Salminen JK, Nagren K, Aalto S, Hietala J (2010) Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder. Psychological Medicine 40:523-8
121. Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A (2010) Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol Psychiatry 68:634-41
122. Kiesewetter DO, Jagoda EM, Starrett Jr JE, Gribkoff VK, Hewawasam P, Srinivas N, Salazar D, Eckelman WC (2002) Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener. Nucl Med Biol 29:55-9 (Pubitemid 34088163)
123. Kim YH, Kang HC, Kim DS, Kim SH, Shim KW, Kim HD, Lee JS (2011) Neuroimaging in identifying focal cortical dysplasia and prognostic factors in pediatric and adolescent epilepsy surgery. Epilepsia 52:722-7
124. Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, Kreek MJ (2000) Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295:1070-6
125. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-19 (Pubitemid 38269583)
126. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM (1998a) Evidence for striatal dopamine release during a video game. Nature 393:266-8 (Pubitemid 28261725)
127. Koepp MJ, Richardson MP, Brooks DJ, Cunningham VJ, Duncan JS (1997) Central benzodiazepine/gamma-aminobutyric acid A receptors in idiopathic generalized epilepsy: an [11C]flumazenil positron emission tomography study. Epilepsia 38:1089-97 (Pubitemid 27424152)
128. Koepp MJ, Richardson MP, Brooks DJ, Duncan JS (1998b) Focal cortical release of endogenous opioids during reading-induced seizures. Lancet 352:952-5 (Pubitemid 28427280)
129. Koeppe RA, Gilman S, Junck L,Wernette K, Frey KA (2008) Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4:S67-76
130. Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Nagren K, Helin S, Parkkola R, Viitanen M, Rinne JO (2011) Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 76:1085-90
131. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, Hauser RA, Smith DA, Nauert GM, Perl DP, Olanow CW (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332:1118-24
132. Kuhl DE, Hoffman EJ, Phelps ME, Ricci AR, Reivich M (1976) Design and application of the Mark IV scanning system for radionuclide computed tomography of the brain. IAEA Symp Med Radionuclide Imaging 1:309-20
133. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey
134. Kumar A, Juhasz C, Asano E, Sood S, Muzik O, Chugani HT (2010) Objective detection of epileptic foci by 18FFDG PET in children undergoing epilepsy surgery. J Nucl Med 51:1901-7
135. Lamare F, Hinz R, Gaemperli O, Pugliese F, Mason JC, Spinks T, Camici PG, Rimoldi OE (2011) Detection and quantification of large-vessel inflammation with 11C-(R)-PK11195 PET/CT. J Nucl Med 52:33-9
136. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-8
137. Lammertsma AA, Jones T (1983) Correction for the presence of intravascular oxygen-15 in the steady-state technique for measuring regional oxygen extraction ratio in the brain: 1. Description of the method. J Cereb Blood Flow Metab 3:416-24 (Pubitemid 14182285)
138. Lange K, Carson R (1984) EM reconstruction algorithms for emission and transmission tomography. J Comp Assist Tomogr 8:306
139. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J (2007) Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry 61: 1081-9 (Pubitemid 46551966)
140. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-51 (Pubitemid 30164887)
141. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46:56-72 (Pubitemid 29296818)
142. Laruelle M, Kegeles LS, Abi-Dargham A (2003) Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann NY Acad Sci 1003:138-58 (Pubitemid 38083052)
143. Laufs H, Richardson MP, Salek-Haddadi A, Vollmar C, Duncan JS, Gale K, Lemieux L, Loscher W, Koepp MJ (2011) Converging PETand fMRI evidence for a common area involved in human focal epilepsies. Neurology 77:904-10
144. Leblanc R, Tyler JL, Mohr G, Meyer E, Diksic M, Yamamoto L, Taylor L, Gauthier S, Hakim A (1987a) Hemodynamic and metabolic effects of cerebral revascularization. J Neurosurg 66:529-35 (Pubitemid 17059507)
145. Leblanc R, Yamamoto YL, Tyler JL, Diksic M, Hakim A (1987b) Borderzone ischemia. Ann Neurol 22:707-13 (Pubitemid 18018466)
146. Lenzi GL, Frackowiak RS, Jones T (1982) Cerebral oxygen metabolism and blood flow in human cerebral ischemic infarction. J Cereb Blood Flow Metab 2:321-35 (Pubitemid 12015758)
147. Lenzi GL, Jones T, McKenzie CG, Moss S (1978) Noninvasive regional study of chronic cerebrovascular disorders using the oxygen-15 inhalation technique. J Neurol Neurosurg Psychiatry 41:11-7 (Pubitemid 8295729)
148. Lenzi GL, Jones T, Reid JL, Moss S (1979) Regional impairment of cerebral oxidative metabolism in Parkinson's disease. J Neurol Neurosurg Psychiatry 42:59-62 (Pubitemid 9083202)
149. Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A (2002) Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 27:1027-35 (Pubitemid 35447639)
150. Lingford-Hughes A, Reid AG, Myers J, Feeney A, Hammers A, Taylor L, Rosso L, Turkheimer F, Brooks DJ, Grasby P, Nutt DJ (2012) A [11c]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced a5 benzodiazepine receptors in limbic regions. J Psychopharmacol 26:273-81
151. Lueck CJ, Zeki S, Friston KJ, Deiber MP, Cope P, Cunningham VJ, Lammertsma AA, Kennard C, Frackowiak RS (1989) The colour centre in the cerebral cortex of man. Nature 340:386-9 (Pubitemid 19191603)
152. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D (2010) Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med 51:7-15
153. MacDonald SW, Cervenka S, Farde L, Nyberg L, Backman L (2009) Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recog-nition and executive functioning. Neuropsychologia 47:2299-304
154. Marazano C, Maziere M, Berger G, Comar D (1977) Synthesis of methyl iodide-11 C and formaldehyde-11 C. Int J Appl Radiat Isot 28:49-52
155. Marchal G, Rioux P, Petit-Tabou MC, Derlon JM, Baron JC, Serrati C, Viader F, de la Sayette V, Le Doze F, Lochon P, Petit-Taboué MC, Orgogozo JM (1993) PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet 341:925-7 (Pubitemid 23109112)
156. Marner L, Gillings N, Comley RA, Baare WFC, Rabiner EA, Wilson AA, Houle S, Hasselbalch SG, Svarer C, Gunn RN, Laruelle M, Knudsen GM (2009) Kinetic Modeling of 11C-SB207145 Binding to 5-HT4 Receptors in the Human Brain In Vivo. J Nucl Med 50:900-8
157. Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A, Kegeles L, Talbot P, Evans S, Krystal J, Laruelle M, Abi-Dargham A (2005) Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58:779-86 (Pubitemid 41677416)
158. Martinez D, Greene K, Broft A, Kumar D, Liu F, Narendran R, Slifstein M, Van Heertum R, Kleber HD (2009) Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 166:1170-7
159. Martinez D, Narendran R (2010) Imaging neurotransmitter release by drugs of abuse. Curr Top Behav Neurosci 3:219-45
160. Martinez D, Narendran R, Foltin RW, Slifstein M, Hwang DR, Broft A, Huang Y, Cooper TB, Fischman MW, Kleber HD, Laruelle M (2007) Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 164:622-9 (Pubitemid 46650194)
161. McKenzie CG, Lenzi GL, Jones T, Moss S (1978) Radioactive oxygen 15O studies in cerebral neoplasms. J R Soc Med 71:417-25
162. Melcher CL, Schweitzer JS (1992) A promising new scintillator: cerium-doped lutetium oxyorthosilicate. Nucl Instrum Methods Phys Res A 314:212-4
163. Melichar JK, Hume SP, Williams TM, Daglish MR, Taylor LG, Ahmad R, Malizia AL, Brooks DJ, Myles JS, Lingford-Hughes A, Nutt DJ (2005) Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 312:309-15 (Pubitemid 40096483)
164. Mentis MJ, Dhawan V, Nakamura T, Ghilardi MF, Feigin A, Edwards C, Ghez C, Eidelberg D (2003) Enhancement of brain activation during trial-and-error sequence learning in early PD. Neurology 60:612-9 (Pubitemid 36246078)
165. Meyer JH (2008) Applying neuroimaging ligands to study major depressive disorder. Semin Nucl Med 38:287-304 (Pubitemid 351726327)
166. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S (2006) Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63:1209-16 (Pubitemid 44708079)
167. Meyer JH, Goulding VS,Wilson AA, Hussey D, Christensen BK, Houle S (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 163:102-5 (Pubitemid 34985318)
168. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P (2003) Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 160:90-9 (Pubitemid 36042431)
169. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-35 (Pubitemid 38625335)
170. Meyer JH, Wilson AA, Sagrati S, Miler L, Rusjan P, Bloomfield PM, Clark M, Sacher J, Voineskos AN, Houle S (2009) Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry 66:1304-12
171. Minoshima S, Frey KA, Cross DJ, Kuhl DE (2004) Neurochemical imaging of dementias. Semin Nucl Med 34:70-82 (Pubitemid 38056405)
172. Mintun MA, Raichle ME, Martin WR, Herscovitch P (1984) Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med 25:177-87 (Pubitemid 14187475)
173. Miyake N, Skinbjerg M, Easwaramoorthy B, Kumar D, Girgis RR, Xu X, Slifstein M, Abi-Dargham A (2011) Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer [11C] ABP688 and N-acetylcysteine challenge. Biol Psychiatry 69:822-4
174. Moresco FM, Dieci M, Vita A, Messa C, Gobbo C, Galli L, Rizzo G, Panzacchi A, De Peri L, Invernizzi G, Fazio F (2002) In vivo serotonin 5HT(2A) receptor binding and personality traits in healthy subjects: a positron emission tomography study. Neuroimage 17:1470-8 (Pubitemid 35333866)
175. Moustafa RR, Izquierdo-Garcia D, Jones PS, Graves MJ, Fryer TD, Gillard JH, Warburton EA, Baron JC (2010) Watershed infarcts in transient ischemic attack/minor stroke with > or = 50% carotid stenosis: hemodynamic or embolic? Stroke 41:1410-6
176. Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ (1992) Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 12:571-83
177. Muraishi K, Kameyama M, Sato K, Sirane R, Ogawa A, Yoshimoto T, Hatazawa J, Itoh M (1993) Cerebral circulatory and metabolic changes following EC/IC bypass surgery in cerebral occlusive diseases. Neurol Res 15:97-103 (Pubitemid 23131419)
178. Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R, Greene P, Fahn S, Freed C, Eidelberg D (2001) Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol 50:181-7 (Pubitemid 32738142)
179. Nash JR, Sargent PA, Rabiner EA, Hood SD, Argyropoulos SV, Potokar JP, Grasby PM, Nutt DJ (2008) Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br J Psychiatry 193:229-34
180. Neumeister A, Bain E, Nugent AC, Carson RE, Bonne O, Luckenbaugh DA, Eckelman W, Herscovitch P, Charney DS, Drevets WC (2004) Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci 24:589-91 (Pubitemid 38166482)
181. Nikolaus S, Antke C, Beu M, Muller HW (2010) Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders-results from in vivo imaging studies. Rev Neurosci 21:119-39
182. Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17:97-103
183. Nortje J, Coles JP, Timofeev I, Fryer TD, Aigbirhio FI, Smielewski P, Outtrim JG, Chatfield DA, Pickard JD, Hutchinson PJ, Gupta AK, Menon DK (2008) Effect of hyperoxia on regional oxygenation and metabolism after severe traumatic brain injury: preliminary findings. Crit Care Med 36:273-81
184. Nutt R, Vento LJ, Ridinger MH (2007) In vivo molecular imaging biomarkers: clinical pharmacology's new 'PET'? Clin Pharmacol Ther 81:792-5 (Pubitemid 46788307)
185. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, Bullock R, Walker Z, Kennedy A, Fox NC, Rossor MN, Rinne JO, Brooks DJ (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73:754-60
186. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB (2003) A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-14 (Pubitemid 37072046)
187. Oswald LM, Wong DF, Zhou Y, Kumar A, Brasic J, Alexander M, Ye W, Kuwabara H, Hilton J, Wand GS (2007) Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release. Neuroimage 36:153-66 (Pubitemid 46617942)
188. Pantano P, Baron JC, Samson Y, Bousser MG, Derouesne C, Comar D (1986) Crossed cerebellar diaschisis. Further studies. Brain 109(Part 4):677-94 (Pubitemid 16035728)
189. Passchier J, Gentile G, Porter R, Herdon H, Salinas C, Jakobsen S, Audrain H, Laruelle M, Gunn RN (2010) Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 64:542-9
190. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, Zilles K, Coenen HH, Langen KJ (2005) O-(2-[18F]fluoroethyl)-L- tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678-87 (Pubitemid 40380202)
191. Paulesu E, Frith CD, Frackowiak RS (1993) The neural correlates of the verbal component of working memory. Nature 362:342-5 (Pubitemid 23101305)
192. Petersen SE, Fox PT, Posner MI, Mintun M, Raichle ME (1988) Positron emission tomographic studies of the cortical anatomy of single-word processing. Nature 331:585-9 (Pubitemid 18049525)
193. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM (1975) Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16:210-24
194. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6:371-88 (Pubitemid 10203423)
195. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S,Widner H, Lindvall O (1999) Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2:1137-40 (Pubitemid 30126374)
196. Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R, OertelW, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks DJ (2000) Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 48:689-95
197. Pinching AJ, Travers RL, Hughes GR, Jones T, Moss S (1978) Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet 1:898-900 (Pubitemid 8350351)
198. Posner MI, Petersen SE, Fox PT, Raichle ME (1988) Localization of cognitive operations in the human brain. Science 240:1627-31
199. Powers WJ, Martin WR, Herscovitch P, Raichle ME, Grubb Jr RL (1984) Extracranial-intracranial bypass surgery: hemodynamic and metabolic effects. Neurology 34:1168-74 (Pubitemid 14068588)
200. Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH (2008) Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 65:1072-8
201. Price CJ, Wang D, Menon DK, Guadagno JV, Cleij M, Fryer T, Aigbirhio F, Baron JC, Warburton EA (2006) Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 37:1749-53 (Pubitemid 44297724)
202. Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET (2011) Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food rewardrelated brain activation in humans. Mol Psychiatry 16:826-35, 785
203. Rabiner EA, Bhagwagar Z, Gunn RN, Sargent PA, Bench CJ, Cowen PJ, Grasby PM (2001) Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatry 158:2080-2 (Pubitemid 33104122)
204. Rabiner EA, Gunn RN, Castro ME, Sargent PA, Cowen PJ, Koepp MJ, Meyer JH, Bench CJ, Harrison PJ, Pazos A, Sharp T, Grasby PM (2000) b-blocker binding to human 5-HT1A receptors in vivo and in vitro: Implications for antidepressant therapy. Neuropsychopharmacology 23:285-93 (Pubitemid 30609662)
205. Rabiner EA, Messa C, Sargent PA, Husted-Kjaer K, Montgomery A, Lawrence AD, Bench CJ, Gunn RN, Cowen P, Grasby PM (2002) A database of [(11)C]WAY-100635 binding to 5-HT(1A) receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 15:620-32 (Pubitemid 34852530)
206. Ramsay SC, Weiller C, Myers R, Cremer JE, Luthra SK, Lammertsma AA, Frackowiak RS (1992) Monitoring by PET of macrophage accumulation in brain after ischaemic stroke. Lancet 339:1054-5
207. Raynaud C, Todd-Pokropek AE, Comar D, Pizer SM, Kacperek A, Maziere M (1974) A method for investigating regional variations of cerebral uptake of 11C psychotropic drugs in man. In: Dynamic studies with radioisotopes in medicine vol. SM 185/84. International Atomic Energy Agency, 45-56
208. Reader AJ, Sureau FC, Comtat C, Trebossen R, Buvat I (2006) Joint estimation of dynamic PET images and temporal basis functions using fully 4D ML-EM. Phys Med Biol 51:5455-74 (Pubitemid 44773325)
209. Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, Solbach C, Reischl G, Schwarzler F, Grunder G, Machulla HJ, Bares R, Heinz A (2008) Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol Psychiatry 13:606-13, 557 (Pubitemid 351704938)
210. Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, Thomas DG, Jones T (1983) In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 14:614-26 (Pubitemid 14211607)
211. Richardson MP, Koepp MJ, Brooks DJ, Duncan JS (1998) 11C-flumazenil PET in neocortical epilepsy. Neurology 51:485-92
212. Ridler K, Plisson C, Rabiner EA, Gunn RN, Easwaramoorthy B, Abi-Dargham A, Laruelle M, Slifstein M (2011) Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: a positron emission tomography study in Papio anubis. Synapse 65:1119-27
213. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnstrom P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL (2002) Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105:2708-11 (Pubitemid 34615139)
214. Ruhe HG, Booij J, Reitsma JB, Schene AH (2009) Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender. Eur J Nucl Med Mol Imaging 36:841-9
215. Ryvlin P, Bouvard S, Le Bars D, De Lamerie G, Gregoire MC, Kahane P, Froment JC, Mauguiere F (1998) Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. Brain 121(Part 11): 2067-81 (Pubitemid 28497905)
216. Sacher J, Houle S, Parkes J, Rusjan P, Sagrati S, Wilson AA, Meyer JH (2011) Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [(11)C]-harmine PET study. J Psychiatry Neurosci 36:375-82
217. Sacher J, Wilson AA, Houle S, Rusjan P, Hassan S, Bloomfield PM, Stewart DE, Meyer JH (2010) Elevated brain monoamine oxidase A binding in the early postpartum period. Arch Gen Psychiatry 67:468-74
218. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E, Jones T, Price P (2003) Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63:2409-15 (Pubitemid 36605177)
219. Samson Y, Baron JC, Bousser MG, Rey A, Derlon JM, David P, Comoy J (1985) Effects of extra-intracranial arterial bypass on cerebral blood flow and oxygen metabolism in humans. Stroke 16:609-16 (Pubitemid 15007233)
220. Sanabria-Bohorquez SM, Joshi AD, Holahan M, Daneker L, Riffel K, Williams M, Li W, Cook JJ, Hamill TG (2012) Quantification of the glycine transporter 1 in rhesus monkey brain using [(18)F]MK-6577 and a model-based input function. Neuroimage 59:2589-99
221. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ (2000) Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57:174-80 (Pubitemid 30075269)
222. Savic I, Pauli S, Thorell JO, Blomqvist G (1994) In vivo demonstration of altered benzodiazepine receptor density in patients with generalised epilepsy. J Neurol Neurosurg Psychiatry 57:797-804 (Pubitemid 24214959)
223. Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L (1988) In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 2:863-6
224. Savitz JB, Drevets WC (2009) Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 164:300-30
225. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Popperl G, Holtmannspotter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M, Beer AJ (2009) Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 11:861-70
226. Schreckenberger M, Klega A, Grunder G, Buchholz HG, Scheurich A, Schirrmacher R, Schirrmacher E, Muller C, Henriksen G, Bartenstein P (2008) Opioid receptor PET reveals the psychobiologic correlates of reward processing. J Nucl Med 49:1257-61
227. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-9
228. Serrati C, Marchal G, Rioux P, Viader F, Petit-Taboue MC, Lochon P, Luet D, Derlon JM, Baron JC (1994) Contralateral cerebellar hypometabolism: a predictor for stroke outcome? J Neurol Neurosurg Psychiatry 57: 174-9 (Pubitemid 24050456)
229. Sette G, Baron JC, Mazoyer B, Levasseur M, Pappata S, Crouzel C (1989) Local brain haemodynamics and oxygen metabolism in cerebrovascular disease. Positron emission tomography. Brain 112(Part 4):931-51 (Pubitemid 19199477)
230. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, Jones T, Frackowiak RSJ (1995) A functional neuroanatomy of hallucinations in schizophrenia. Nature 378:176-9
231. Silbersweig DA, Stern E, Frith CD, Cahill C, Schnorr L, Grootoonk S, Spinks T, Clark J, Frackowiak R, Jones T (1993) Detection of thirty-second cognitive activations in single subjects with positron emission tomography: a new low-dose H2(15)O regional cerebral blood flow three-dimensional imaging technique. J Cereb Blood Flow Metab 13:617-29 (Pubitemid 23187505)
232. Smith DF, Jakobsen S (2009) Molecular tools for assessing human depression by positron emission tomography. Eur Neuropsychopharmacol 19:611-28
233. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H (1993) Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34:324-30 (Pubitemid 23259600)
234. Sobesky J, Thiel A, Ghaemi M, Hilker RH, Rudolf J, Jacobs AH, Herholz K, Heiss WD (2005a) Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab 25:1685-91 (Pubitemid 41683179)
235. Sobesky J, Weber OZ, Lehnhardt F-G, Hesselmann V, Neveling M, Jacobs A, Heiss W-D (2005b) Does the mismatch match the penumbra? Stroke 36:980-5
236. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916 (Pubitemid 8098854)
237. Soliman A, Bagby RM, Wilson AA, Miler L, Clark M, Rusjan P, Sacher J, Houle S, Meyer JH (2011) Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. Psychol Med 41:1051-60
238. Soloff PH, Price JC, Mason NS, Becker C, Meltzer CC (2010) Gender, personality, and serotonin-2A receptor binding in healthy subjects. Psychiatry Res 181:77-84
239. Sossi V, de La Fuente-Fernandez R, Holden JE, Doudet DJ, McKenzie J, Stoessl AJ, Ruth TJ (2002) Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 Ffluorodopa data. J Cereb Blood Flow Metab 22:232-9 (Pubitemid 34135654)
240. Souza F, Simpson N, Raffo A, Saxena C, Maffei A, Hardy M, Kilbourn M, Goland R, Leibel R, Mann JJ, Van Heertum R, Harris PE (2006) Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J Clin Invest 116:1506-13
241. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, Adamsen TC, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA (2008) Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 14:2623-30
242. Stoessl AJ, Brooks DJ, Eidelberg D (2011) Milestones in neuroimaging. Mov Disord 26:868-978
243. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-96 (Pubitemid 40349501)
244. Sureau FC, Reader AJ, Comtat C, Leroy C, Ribeiro MJ, Buvat I, Trebossen R (2008) Impact of image-space resolution modeling for studies with the high-resolution research tomograph. J Nucl Med 49:1000-8 (Pubitemid 351793442)
245. Takasawa M, Jones PS, Guadagno JV, Christensen S, Fryer TD, Harding S, Gillard JH, Williams GB, Aigbirhio FI, Warburton EA, Ostergaard L, Baron JC (2008) How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke 39:870-7 (Pubitemid 351619576)
246. Tang CC, Poston KL, Dhawan V, Eidelberg D (2010) Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 30:1049-56
247. Tauscher J, Bagby RM, Javanmard M, Christensen BK, Kasper S, Kapur S (2001) Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. Am J Psychiatry 158:1326-8 (Pubitemid 32717713)
248. Tauscher J, Kapur S (2001) Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 15:671-8 (Pubitemid 33701934)
249. Ter-Pogossian MM, Eichling JO, Davis DO,Welch MJ (1970) The measure in vivo of regional cerebral oxygen utilization by means of oxyhemoglobin labeled with radioactive oxygen-15. J Clin Invest 49:381-91
250. Ter-Pogossian MM, Herscovitch P (1985) Radioactive oxygen-15 in the study of cerebral blood flow, blood volume, and oxygen metabolism. Semin Nucl Med 15:377-94
251. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA (1975) A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology 114:89-98
252. Ter-Pogossian MM, Powers WE (1957) The use of radioactive oxygen-15 in the determination of oxygen content in malignant neoplasms. In: Radioisotopes in Scientific Research, volume 3. Proceedings of the 1st UNESCO International Conference (Paris). Paris: Pergamon Press
253. Ter-Pogossian MM, Taveras JM, Davis DO, Eichling JO (1969) A study of regional cerebral oxygen supply and utilization by means of radioactive oxygen-15. In: Recent advances in the study of circulation (Taveras JM, Fischgold H, Dilenge D, eds). Springfield, Illanois: Thomas, 156-74
254. The theory and practice of 3D PET (Bendrium B, Townsend DW, eds). Dordrecht: Kluwer Academic Publisher, 1998
255. Tomasi G, Bertoldo A, Bishu S, Unterman A, Smith CB, Schmidt KC (2009) Voxel-based estimation of kinetic model parameters of the L-[1-(11)C]leucine PET method for determination of regional rates of cerebral protein synthesis: validation and comparison with region-ofinterest-based methods. J Cereb Blood Flow Metab 29:1317-31
256. Turkheimer FE, Banati RB, Visvikis D, Aston JA, Gunn RN, Cunningham VJ (2000) Modeling dynamic PET-SPECT studies in the wavelet domain. J Cereb Blood Flow Metab 20:879-93 (Pubitemid 30317063)
257. Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, Raichle ME (2010) Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci USA 107:17757-62
258. van Assema DME, Lubberink M, Bauer M, van der Flier WM, Schuit RC, Windhorst AD, Comans EFI, Hoetjes NJ, Tolboom N, Langer O, Muller M, Scheltens P, Lammertsma AA, van Berckel BNM (2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135:181-9
259. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS (2008) Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64:820-2
260. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N (1997) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-3 (Pubitemid 27181256)
261. Wagner Jr HN, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221:1264-6 (Pubitemid 13001277)
262. Weiller C, Isensee C, Rijntjes M, Huber W, Muller S, Bier D, Dutschka K, Woods RP, Noth J, Diener HC (1995) Recovery from Wernicke's aphasia: a positron emission tomographic study. Ann Neurol 37:723-32
263. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Bjorklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O (1997) Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42:95-107 (Pubitemid 27304785)
264. Wienhard K, Schmand M, Casey ME, Baker K, Bao J, Eriksson L, Jones WF, Knoess C, Lenox M, Lercher M, Luk P, Michel C, Reed JH, Richerzhagen N, Treffert J, Vollmar S, Young JW, Heiss WD, Nutt R (2002) The ECAT HRRT: performance and first clinical application of the new high resolution research tomograph. IEEE Trans Nucl Sci 49:104-10 (Pubitemid 34658201)
265. Willemsen AT, van Waarde A, Paans AM, Pruim J, Luurtsema G, Go KG, Vaalburg W (1995) In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET. J Nucl Med 36:411-9
266. Williams TM, Daglish MR, Lingford-Hughes A, Taylor LG, Hammers A, Brooks DJ, Grasby P, Myles JS, Nutt DJ (2007) Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. Br J Psychiatry 191:63-9 (Pubitemid 47035183)
267. Williams TM, Davies SJ, Taylor LG, Daglish MR, Hammers A, Brooks DJ, Nutt DJ, Lingford-Hughes A (2009) Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol 19:740-8
268. Willmann O, Wennberg R, May T, Woermann FG, Pohlmann-Eden B (2007) The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy A meta-analysis. Seizure 16:509-20 (Pubitemid 47209240)
269. Wise RJ, Bernardi S, Frackowiak RS, Legg NJ, Jones T (1983) Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain 106(Pt 1):197-222 (Pubitemid 13152393)
270. Witte AV, Floel A, Stein P, Savli M, Mien LK, Wadsak W, Spindelegger C, Moser U, Fink M, Hahn A, Mitterhauser M, Kletter K, Kasper S, Lanzenberger R (2009) Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. Hum Brain Mapp 30:2558-70
271. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD,Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557-68
272. Zald DH, Cowan RL, Riccardi P, Baldwin RM, Ansari MS, Li R, Shelby ES, Smith CE, McHugo M, Kessler RM (2008) Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humans. J Neurosci 28:14372-8
273. Zamuner S, Gomeni R, Bye A (2002) Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. Nucl Med Biol 29:115-23 (Pubitemid 34088167)
274. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J (2009) The performance of MRI-based cerebral blood flow measurements in acute and subacute stroke compared with 15O-water positron emission tomography: identification of penumbral flow. Stroke 40: 2413-2421
275. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J (2010) Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke 41:2817-21
276. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ (1996) Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2:1225-9 (Pubitemid 26375406)
277. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS (2001) Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293:311-5 (Pubitemid 32694749)